Alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are main causes of chronic liver disease in the Western countries. Both ALD and NAFLD represent a broad spectrum of disorders ranging from simple steatosis to steatohepatitis and cirrhosis. ALD is caused by acute or chronic alcohol consumption while NAFLD is defined as the presence of hepatic steatosis in the absence of other causes of secondary fat accumulation such as significant alcohol consumption or hereditary disorders. NAFLD is a complex disease with genetic and environmental factors, being often associated with metabolic risk factors such as obesity and diabetes. Remarkably, the binge drinking represents a growing specific alcohol consumption pattern. The binge drinking is at the same time a predictor of fibrosis progression and a consolidated risk factor for obesity representing an ideal “common land” between ALD and NAFLD. In the recent years, new diagnostic tools and many experimental drugs have been proposed for both ALD and NAFLD.

We mainly welcome scientists to contribute with original, clinical studies, and review articles describing the state of the art of diagnostic and pharmacological issues regarding both ALD and NAFLD. This special issue aims to interest both practitioners and researchers in the areas of hepatology, gastroenterology, internal medicine, and toxicology.

Potential topics include but are not limited to the following:

• Preventive health policies for alcoholic and nonalcoholic liver disease
• Main tools for early diagnosis of steatosis and steatohepatitis
• Diagnostic approach toward alcoholic and nonalcoholic advanced liver disease: similitudes and differences
• New perspectives for the treatment of alcohol use disorder
• Experimental drugs for nonalcoholic liver disease: lights and shadows
• Psychological interventions for patients with alcohol-related or metabolic liver disease
• Binge drinking: diagnostic approach and treatment options